Tara Bancroft is ranked #1121 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Tara Bancroft

Tara Bancroft

Q: How accurate are Tara Bancroft's stock ratings?

About 59% of Tara's ratings were profitable over a one-year hold, with an average return of +2.7% per rating, measured by 13Foresight from historical prices.

TD Cowen

Wall Street Analyst

★★★☆☆

#1121

on 13Foresight · ranked by our own returns

57%

Success Rate

+2.5%

Average Return

28 of 49 calls profitable · -1.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 57% of Tara Bancroft's ratings turned a profit when each position was held for 1 year — averaging +2.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

102 Buy 21 Hold 0 Sell

Tara's Stock Coverage 26 ratings · 2026-08-31

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
CELC Celcuity	Aug 13, 2026	BUY	Strong Buy +37.6% avg upside 16 analysts	—	+2.8%	·
FATE Fate Therapeutics	Aug 13, 2026	HOLD	Buy +401.2% avg upside 31 analysts	—	+0.8%	·
MGNX MacroGenics	Aug 13, 2026	HOLD	Buy +333.2% avg upside 25 analysts	—	-1.5%	·
TCRX TScan Therapeutics	Aug 12, 2026	BUY	Strong Buy +1040.1% avg upside 12 analysts	—	-3.0%	·
STRO Sutro Biopharma	Aug 12, 2026	BUY	Strong Buy +104.7% avg upside 21 analysts	—	-4.0%	·
VALN Valneva	Aug 11, 2026	BUY	Buy +76.5% avg upside 6 analysts	$12.00 86.71% Upside	+15.0%	·
RCKT Rocket Pharmaceuticals	Aug 10, 2026	HOLD	Buy +338.6% avg upside 29 analysts	—	+6.0%	·
WHWK Whitehawk Therapeutics	Aug 06, 2026	HOLD	Strong Buy +171.4% avg upside 14 analysts	—	-3.4%	·
EYPT EyePoint Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +430.9% avg upside 21 analysts	$20.00 346.41% Upside	-58.8%	·
GERN Geron	Aug 05, 2026	BUY	Strong Buy +185.8% avg upside 19 analysts	$3.00 98.67% Upside	-6.1%	·
XNCR Xencor	Aug 05, 2026	BUY	Strong Buy +32.4% avg upside 27 analysts	—	+31.4%	·
PTGX Protagonist Therapeutics	Aug 05, 2026	BUY	Strong Buy -16.6% avg upside 19 analysts	$155.00 7.43% Upside	+7.6%	·
URGN Urogen Pharma	Aug 05, 2026	BUY	Strong Buy +8.2% avg upside 16 analysts	$60.00 37.58% Upside	-2.0%	·
PCVX Vaxcyte	Aug 05, 2026	BUY	Strong Buy +73.8% avg upside 15 analysts	$75.00 25.37% Upside	+7.0%	·
LNTH Lantheus	Aug 03, 2026	HOLD	Buy -19.7% avg upside 21 analysts	$102.50 1.66% Upside	-0.4%	·
OCUL Ocular Therapeutix	Aug 03, 2026	BUY	Strong Buy +139.1% avg upside 21 analysts	$20.00 92.96% Upside	+28.8%	·
TGTX TG Therapeutics	Aug 03, 2026	BUY	Strong Buy -17.3% avg upside 20 analysts	$75.00 39.04% Upside	+16.8%	·
IRON Disc Medicine	Jul 30, 2026	BUY	Strong Buy +9.6% avg upside 21 analysts	—	+1.0%	·
BCYC Bicycle Therapeutics	Jul 30, 2026	BUY	Strong Buy +475.8% avg upside 21 analysts	—	+8.0%	·
KLRS Kalaris Therapeutics	Jun 15, 2026	BUY	Buy +218.1% avg upside 13 analysts	—	-4.5%	·
MLYS Mineralys Therapeutics, Inc.	May 06, 2026	BUY	Strong Buy +78.5% avg upside 12 analysts	—	-15.0%	·
NBTX Nanobiotix	Apr 01, 2026	BUY	Strong Buy -18.8% avg upside 5 analysts	—	+19.3%	·
AU:TLX Telix Pharmaceuticals	Feb 19, 2026	BUY	Strong Buy +63.1% avg upside 14 analysts	$20.00 29.83% Upside	+50.0%	·
NCNA Nucana	Mar 14, 2025	HOLD	Buy +696.3% avg upside 9 analysts	—	·	·
IMA ImageneBio	Aug 09, 2024	BUY	Buy +246.5% avg upside 13 analysts	—	-24.8%	·
CBIO Crescent Biopharma	Jul 26, 2024	HOLD	Strong Buy +26.4% avg upside 17 analysts	—	-44.6%	·

🔒 21 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Tara Bancroft — Frequently Asked Questions

How accurate are Tara Bancroft's stock ratings?

Based on the calls 13Foresight could measure, about 59% of Tara's ratings were profitable over a one-year hold, with an average return of +2.7% per rating, or -0.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Tara ranked on 13Foresight?

Tara Bancroft is currently ranked #1121 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Tara cover?

Tara most recently has ratings on CELC, FATE, MGNX, TCRX, STRO, VALN, RCKT, WHWK, EYPT, GERN, XNCR, PTGX and 14 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Tara Bancroft

Rating Distribution

Welcome to 13Foresight!